Recipient Title Director, QA, 265 Livingston Street Northvale , NJ 07647-1901 United StatesFEI 3012113519Issued Apr 14, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3012113519.
Violations6
Issue DateApr 14, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
New Life Pharma LLC
Location
Recipient Title Director, QA, 265 Livingston Street Northvale , NJ 07647-1901 United States
FEI Number
3012113519
Country
United States
Issue Date
April 14, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Subject
CGMP/Adulterated and Unapproved New Drug/Misbranded
New Life Pharma LLC FDA Warning Letter, April 14, 2026
Talk to a Specialist